Report from Annual General Meeting in Vigmed Holding
On May 13, 2015, Vigmed Holding AB (publ) held its Annual General Meeting. At the AGM, 17, 742, 318 shares were represented, 41 % of all shares. A summary of the resolutions follows below. All resolutions were passed with the required majority.
The AGM resolved to adopt the presented Income Statement and Balance Sheet, and the Consolidated Income Statement and Consolidated Balance Sheet. The Meeting also resolved to appropriate the Company’s profit or loss in accordance with the Board of Directors’ proposal in the Annual Accounts. Additionally, the Meeting resolved that no dividend is paid for the financial year 2014.
The AGM resolved to discharge the Board members and Chief Executive Officer from liability.
The AGM resolved that the Board of Directors will consist of Lennart Holm, Per Knutsson, Rikard Roos, Mikael Karlsson, Lennart Dreyer, Thomas Baier, Axel Sjöblad and Philip Nyblaeus. Lennart Holm was re-elected as Chairman of the Board. The remuneration shall be SEK 150,000 to the Chairman and SEK 85,000 to every Board member who is not employed by the company.
The AGM also resolved that, as in the previous year, auditors’ fees are payable in accordance with approved account, on the customary debiting terms. It was resolved that AB Öhrlings PricewaterhouseCoopers continue as the Company’s auditor and that responsible accountant is Christer Kilefors.
The Annual General Meeting decided to grant the Board of Directors authorization, to decide on new share issue, on one or more occasions during the period until the next AGM, with or without waiving shareholders preferential rights. Issues may be made with or without the provision of contribution, set-off or other terms. The number of shares to be issued may not exceed a total of 10,958,333. Dilution of capital may, upon full exercise of the authorization, amount to no more than about 20 percent of the registered share capital at the time of the Annual General Meeting. The intention of the authorization is to enable the raise of working capital, to finance expansion of the sales and marketing organization and to initiate the development of new product lines. To the extent the authorization is used for issue against cash payment waiving the shareholders’ preferential rights, the issue price should be market-based. The resolution was made in accordance with the proposal, see item 15, in the notice to the AGM published 13 April 2015.
Helsingborg, May 15 2015
Vigmed Holding AB
For further information contact:
Chairman of the board, Lennart Holm +46 70 630 8562
Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood-borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden, and has 20 employees. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 600 shareholders. Remium Nordic AB is the Company’s Certified Advisor.
Additional information about the company can be found on Vigmed’s website: www.vigmed.com/investor